Local vascular gene therapy with apolipoprotein A-I to promote regression of atherosclerosis

Arteriosclerosis, Thrombosis, and Vascular Biology

Volumn 37, Issue 2, 2017, Pages 316-327

  Wacker, Bradley K ^a   Dronadula, Nagadhara ^a   Zhang, Jingwan ^a   Dichek, David A ^a  

^a UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

Author keywords

apolipoprotein A I; atherosclerosis; carotid arteries; genetic therapy; macrophages; rabbits

Indexed keywords

APOLIPOPROTEIN A1; CHOLESTEROL; HELPER DEPENDENT ADENOVIRAL VECTOR; INTERCELLULAR ADHESION MOLECULE 1; VASCULAR CELL ADHESION MOLECULE 1; LIPID;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTERIAL SMOOTH MUSCLE; ARTERY INTIMA; ARTICLE; ATHEROGENIC DIET; CAROTID ARTERY; CAROTID ATHEROSCLEROSIS; CHOLESTEROL BLOOD LEVEL; CHOLESTEROL INTAKE; CONTROLLED STUDY; DRUG EFFICACY; GENOME; INTRALUMINAL DRUG ADMINISTRATION; MACROPHAGE; NONHUMAN; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; REMISSION; T LYMPHOCYTE; VIRAL GENE DELIVERY SYSTEM; ADENOVIRIDAE; ANIMAL; ATHEROSCLEROSIS; ATHEROSCLEROTIC PLAQUE; BIOSYNTHESIS; BLOOD; CAROTID ARTERY DISEASE; COMMON CAROTID ARTERY; DISEASE MODEL; GENE THERAPY; GENE VECTOR; GENETIC TRANSDUCTION; GENETICS; LEPORIDAE; MALE; METABOLISM; NEOINTIMA; PATHOLOGY; PROCEDURES; TIME FACTOR; VASCULAR SMOOTH MUSCLE;

ADENOVIRIDAE; ANIMALS; APOLIPOPROTEIN A-I; ATHEROSCLEROSIS; CAROTID ARTERY DISEASES; CAROTID ARTERY, COMMON; DIET, ATHEROGENIC; DISEASE MODELS, ANIMAL; GENETIC THERAPY; GENETIC VECTORS; INTERCELLULAR ADHESION MOLECULE-1; LIPIDS; MACROPHAGES; MALE; MUSCLE, SMOOTH, VASCULAR; NEOINTIMA; PLAQUE, ATHEROSCLEROTIC; RABBITS; REMISSION INDUCTION; T-LYMPHOCYTES; TIME FACTORS; TRANSDUCTION, GENETIC; VASCULAR CELL ADHESION MOLECULE-1;

EID: 85004011287     PISSN: 10795642     EISSN: 15244636     Source Type: Journal    
DOI: 10.1161/ATVBAHA.116.308258     Document Type: Article

References (63)

1. Tabas I, Garcia-Cardena G, Owens GK. Recent insights into the cellular biology of atherosclerosis. J Cell Biol. 2015;209:13-22. doi: 10.1083/ jcb.201412052.
2. Nissen SE, Stroes E, Dent-Acosta RE, et al; GAUSS-3 Investigators. Efficacy and tolerability of evolocumab vs ezetimibe in patients with muscle-related statin intolerance: The GAUSS-3 Randomized Clinical Trial. JAMA. 2016;315:1580-1590. doi: 10.1001/jama.2016.3608.
3. Waters DD, Hsue PY, Bangalore S. PCSK9 inhibitors for statin intolerance? JAMA. 2016;315:1571-1572. doi: 10.1001/jama.2016.3670.
4. Mampuya WM, Frid D, Rocco M, Huang J, Brennan DM, Hazen SL, Cho L. Treatment strategies in patients with statin intolerance: the Cleveland Clinic experience. Am Heart J. 2013;166:597-603. doi: 10.1016/j. ahj.2013.06.004.
5. Sible AM, Nawarskas JJ, Anderson JR. PCSK9 inhibitors: an innovative approach to treating hyperlipidemia. Cardiol Rev. 2016;24:141-152. doi: 10.1097/CRD.0000000000000102.
6. Feinstein MJ, Lloyd-Jones DM. Monoclonal antibodies for lipid management. Curr Atheroscler Rep. 2016;18:39. doi: 10.1007/s11883-016-0593-2.
7. Verbeek R, Stoekenbroek RM, Hovingh GK. PCSK9 inhibitors: novel therapeutic agents for the treatment of hypercholesterolemia. Eur J Pharmacol. 2015;763(pt A):38-47. doi: 10.1016/j.ejphar.2015.03.099.
8. Barter PJ, Rye KA. Targeting high-density lipoproteins to reduce cardiovascular risk: what is the evidence? Clin Ther. 2015;37:2716-2731. doi: 10.1016/j.clinthera.2015.07.021.
9. Phillips MC. Molecular mechanisms of cellular cholesterol efflux. J Biol Chem. 2014;289:24020-24029. doi: 10.1074/jbc.R114.583658.
10. Lee-Rueckert M, Escola-Gil JC, Kovanen PT. HDL functionality in reverse cholesterol transport-Challenges in translating data emerging from mouse models to human disease. Biochim Biophys Acta. 2016;1861:566-583. doi: 10.1016/j.bbalip.2016.03.004.
11. Khera AV, Cuchel M, de la Llera-Moya M, Rodrigues A, Burke MF, Jafri K, French BC, Phillips JA, Mucksavage ML, Wilensky RL, Mohler ER, Rothblat GH, Rader DJ. Cholesterol efflux capacity, high-density lipoprotein function, and atherosclerosis. N Engl J Med. 2011;364:127-135. doi: 10.1056/NEJMoa1001689.
12. The AIM-HIGH Investigators. Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy. N Engl J Med. 2011;365:2255-2267. doi: 10.1056/NEJMoa1107579.
13. The HPS2-THRIVE Collaborative Group. Effects of extended-release niacin with laropiprant in high-risk patients. N Engl J Med. 2014;371:203-212. doi: 10.1056/NEJMoa1300955.
14. Barter PJ, Rye KA. Cholesteryl ester transfer protein inhibition is not yet dead-pro. Arterioscler Thromb Vasc Biol. 2016;36:439-441. doi: 10.1161/ ATVBAHA.115.306879.
15. Zhao HP, Dia Y, Xiang BR. Discontinued cardiovascular drugs in 2015. Expert Opin Investig Drugs. 2016;25:1093-1101.
16. Tchoua U, D'Souza W, Mukhamedova N, Blum D, Niesor E, Mizrahi J, Maugeais C, Sviridov D. The effect of cholesteryl ester transfer protein overexpression and inhibition on reverse cholesterol transport. Cardiovasc Res. 2008;77:732-739. doi: 10.1093/cvr/cvm087.
17. Briand F, Thieblemont Q, Muzotte E, Burr N, Urbain I, Sulpice T, Johns DG. Anacetrapib and dalcetrapib differentially alters HDL metabolism and macrophage-to-feces reverse cholesterol transport at similar levels of CETP inhibition in hamsters. Eur J Pharmacol. 2014;740:135-143. doi: 10.1016/j.ejphar.2014.06.022.
18. Joy T, Hegele RA. Is raising HDL a futile strategy for atheroprotection? Nat Rev Drug Discov. 2008;7:143-155. doi: 10.1038/nrd2489.
19. Brousseau ME, Diffenderfer MR, Millar JS, Nartsupha C, Asztalos BF, Welty FK, Wolfe ML, Rudling M, Bjorkhem I, Angelin B, Mancuso JP, Digenio AG, Rader DJ, Schaefer EJ. Effects of cholesteryl ester transfer protein inhibition on high-density lipoprotein subspecies, apolipoprotein A-I metabolism, and fecal sterol excretion. Arterioscler Thromb Vasc Biol. 2005;25:1057-1064. doi: 10.1161/01.ATV.0000161928.16334.dd.
20. Ritter MC, Scanus AM. Role of apolipoprotein A-I in the structure of human serum high density lipoproteins. Reconstitution studies. J Biol Chem. 1977;252:1208-1216.
21. Fielding CJ, Fielding PE. Evidence for a lipoprotein carrier in human plasma catalyzing sterol efflux from cultured fibroblasts and its relationship to lecithin:cholesterol acyltransferase. Proc Natl Acad Sci USA. 1981;78:3911-3914.
22. Fielding CJ, Moser K. Evidence for the separation of albumin-and apo A-I-dependent mechanisms of cholesterol efflux from cultured fibroblasts into human plasma. J Biol Chem. 1982;257:10955-10960.
23. Du XM, Kim MJ, Hou L, Le Goff W, Chapman MJ, Van Eck M, Curtiss LK, Burnett JR, Cartland SP, Quinn CM, Kockx M, Kontush A, Rye KA, Kritharides L, Jessup W. HDL particle size is a critical determinant of ABCA1-mediated macrophage cellular cholesterol export. Circ Res. 2015;116:1133-1142. doi: 10.1161/CIRCRESAHA.116.305485.
24. Paszty C, Maeda N, Verstuyft J, Rubin EM. Apolipoprotein AI transgene corrects apolipoprotein E deficiency-induced atherosclerosis in mice. J Clin Invest. 1994;94:899-903. doi: 10.1172/JCI117412.
25. Duverger N, Kruth H, Emmanuel F, Caillaud JM, Viglietta C, Castro G, Tailleux A, Fievet C, Fruchart JC, Houdebine LM, Denefle P. Inhibition of atherosclerosis development in cholesterol-fed human apolipoprotein A-I-transgenic rabbits. Circulation. 1996;94:713-717.
26. Nissen SE, Tsunoda T, Tuzcu EM, Schoenhagen P, Cooper CJ, Yasin M, Eaton GM, Lauer MA, Sheldon WS, Grines CL, Halpern S, Crowe T, Blankenship JC, Kerensky R. Effect of recombinant ApoA-I Milano on coronary atherosclerosis in patients with acute coronary syndromes: a randomized controlled trial. JAMA. 2003;290:2292-2300. doi: 10.1001/ jama.290.17.2292.
27. Tardif JC, Heinonen T, Noble S. High-density lipoprotein/apolipoprotein A-I infusion therapy. Curr Atheroscler Rep. 2009;11:58-63.
28. Hewing B, Parathath S, Barrett T, et al. Effects of native and myeloperoxidase-modified apolipoprotein a-I on reverse cholesterol transport and atherosclerosis in mice. Arterioscler Thromb Vasc Biol. 2014;34:779-789. doi: 10.1161/ATVBAHA.113.303044.
29. Nicholls SJ, Tuzcu EM, Sipahi I, Schoenhagen P, Crowe T, Kapadia S, Nissen SE. Relationship between atheroma regression and change in lumen size after infusion of apolipoprotein A-I Milano. J Am Coll Cardiol. 2006;47:992-997. doi: 10.1016/j.jacc.2005.11.040.
30. Navab M, Anantharamaiah GM, Reddy ST, Hama S, Hough G, Grijalva VR, Yu N, Ansell BJ, Datta G, Garber DW, Fogelman AM. Apolipoprotein A-I mimetic peptides. Arterioscler Thromb Vasc Biol. 2005;25:1325-1331. doi: 10.1161/01.ATV.0000165694.39518.95.
31. Didichenko SA, Navdaev AV, Cukier AM, Gille A, Schuetz P, Spycher MO, Therond P, Chapman MJ, Kontush A, Wright SD. Enhanced HDL functionality in small HDL species produced upon remodeling of HDL by reconstituted HDL, CSL112: effects on cholesterol efflux, anti-inflammatory and antioxidative activity. Circ Res. 2016;119:751-763. doi: 10.1161/ CIRCRESAHA.116.308685.
32. Flynn R, Buckler JM, Tang C, Kim F, Dichek DA. Helper-dependent adenoviral vectors are superior in vitro to first-generation vectors for endothelial cell-targeted gene therapy. Mol Ther. 2010;18:2121-2129. doi: 10.1038/mt.2010.176.
33. Flynn R, Qian K, Tang C, Dronadula N, Buckler JM, Jiang B, Wen S, Dichek HL, Dichek DA. Expression of apolipoprotein A-I in rabbit carotid endothelium protects against atherosclerosis. Mol Ther. 2011;19:1833-1841. doi: 10.1038/mt.2011.133.
34. Du L, Zhang J, De Meyer GR, Flynn R, Dichek DA. Improved animal models for testing gene therapy for atherosclerosis. Hum Gene Ther Methods. 2014;25:106-114. doi: 10.1089/hgtb.2013.199.
35. Daugherty A, Schonfeld G, Sobel BE, Lange LG. Metabolism of very low density lipoproteins after cessation of cholesterol feeding in rabbits. A factor potentially contributing to the slow regression of atheromatous plaques. J Clin Invest. 1986;77:1108-1115. doi: 10.1172/JCI112409.
36. Stein Y, Stein O. Does therapeutic intervention achieve slowing of progression or bona fide regression of atherosclerotic lesions? Arterioscler Thromb Vasc Biol. 2001;21:183-188.
37. Jiang B, Qian K, Du L, Luttrell I, Chitaley K, Dichek DA. Helper-dependent adenovirus is superior to first-generation adenovirus for expressing transgenes in atherosclerosis-prone arteries. Arterioscler Thromb Vasc Biol. 2011;31:1317-1325. doi: 10.1161/ATVBAHA.111.225516.
38. Schulick AH, Dong G, Newman KD, Virmani R, Dichek DA. Endotheliumspecific in vivo gene transfer. Circ Res. 1995;77:475-485.
39. Gruchała M, Bhardwaj S, Pajusola K, Roy H, Rissanen TT, Kokina I, Kholova I, Markkanen JE, Rutanen J, Heikura T, Alitalo K, Bueler H, Yla-Herttuala S. Gene transfer into rabbit arteries with adeno-associated virus and adenovirus vectors. J Gene Med. 2004;6:545-554. doi: 10.1002/ jgm.535.
40. Du L, Dronadula N, Tanaka S, Dichek DA. Helper-dependent adenoviral vector achieves prolonged, stable expression of interleukin-10 in rabbit carotid arteries but does not limit early atherogenesis. Hum Gene Ther. 2011;22:959-968. doi: 10.1089/hum.2010.175.
41. Yamane K, Leung KP. Rabbit M1 and M2 macrophages can be induced by human recombinant GM-CSF and M-CSF. FEBS Open Bio. 2016;6:945-953. doi: 10.1002/2211-5463.12101.
42. Rubin EM, Krauss RM, Spangler EA, Verstuyft JG, Clift SM. Inhibition of early atherogenesis in transgenic mice by human apolipoprotein AI. Nature. 1991;353:265-267. doi: 10.1038/353265a0.
43. Plump AS, Scott CJ, Breslow JL. Human apolipoprotein A-I gene expression increases high density lipoprotein and suppresses atherosclerosis in the apolipoprotein E-deficient mouse. Proc Natl Acad Sci USA. 1994;91:9607-9611.
44. Tangirala RK, Tsukamoto K, Chun SH, Usher D, Pure E, Rader DJ. Regression of atherosclerosis induced by liver-directed gene transfer of apolipoprotein A-I in mice. Circulation. 1999;100:1816-1822.
45. Benoit P, Emmanuel F, Caillaud JM, Bassinet L, Castro G, Gallix P, Fruchart JC, Branellec D, Denefle P, Duverger N. Somatic gene transfer of human ApoA-I inhibits atherosclerosis progression in mouse models. Circulation. 1999;99:105-110.
46. Belalcazar LM, Merched A, Carr B, Oka K, Chen KH, Pastore L, Beaudet A, Chan L. Long-term stable expression of human apolipoprotein A-I mediated by helper-dependent adenovirus gene transfer inhibits atherosclerosis progression and remodels atherosclerotic plaques in a mouse model of familial hypercholesterolemia. Circulation. 2003;107:2726-2732. doi: 10.1161/01.CIR.0000066913.69844.B2.
47. Ishiguro H, Yoshida H, Major AS, Zhu T, Babaev VR, Linton MF, Fazio S. Retrovirus-mediated expression of apolipoprotein A-I in the macrophage protects against atherosclerosis in vivo. J Biol Chem. 2001;276:36742-36748. doi: 10.1074/jbc.M106027200.
48. Raper SE, Chirmule N, Lee FS, Wivel NA, Bagg A, Gao GP, Wilson JM, Batshaw ML. Fatal systemic inflammatory response syndrome in a ornithine transcarbamylase deficient patient following adenoviral gene transfer. Mol Genet Metab. 2003;80:148-158.
49. Brunetti-Pierri N, Ng T, Iannitti D, Cioffi W, Stapleton G, Law M, Breinholt J, Palmer D, Grove N, Rice K, Bauer C, Finegold M, Beaudet A, Mullins C, Ng P. Transgene expression up to 7 years in nonhuman primates following hepatic transduction with helper-dependent adenoviral vectors. Hum Gene Ther. 2013;24:761-765. doi: 10.1089/ hum.2013.071.
50. High KA, Anguela XM. Adeno-associated viral vectors for the treatment of hemophilia. Hum Mol Genet. 2016;25(R1):R36-R41. doi: 10.1093/ hmg/ddv475.
51. Wen S, Graf S, Massey PG, Dichek DA. Improved vascular gene transfer with a helper-dependent adenoviral vector. Circulation. 2004;110:1484-1491. doi: 10.1161/01.CIR.0000141574.78032.A9.
52. Rubin EM, Ishida BY, Clift SM, Krauss RM. Expression of human apolipoprotein A-I in transgenic mice results in reduced plasma levels of murine apolipoprotein A-I and the appearance of two new high density lipoprotein size subclasses. Proc Natl Acad Sci USA. 1991;88:434-438.
53. Huang Y, DiDonato JA, Levison BS, et al. An abundant dysfunctional apolipoprotein A1 in human atheroma. Nat Med. 2014;20:193-203. doi: 10.1038/nm.3459.
54. Feldman LJ, Steg PG, Zheng LP, Chen D, Kearney M, McGarr SE, Barry JJ, Dedieu JF, Perricaudet M, Isner JM. Low-efficiency of percutaneous adenovirus-mediated arterial gene transfer in the atherosclerotic rabbit. J Clin Invest. 1995;95:2662-2671. doi: 10.1172/JCI117968.
55. Williams KJ, Feig JE, Fisher EA. Rapid regression of atherosclerosis: insights from the clinical and experimental literature. Nat Clin Pract Cardiovasc Med. 2008;5:91-102. doi: 10.1038/ncpcardio1086.
56. Badimon JJ, Badimon L, Fuster V. Regression of atherosclerotic lesions by high density lipoprotein plasma fraction in the cholesterol-fed rabbit. J Clin Invest. 1990;85:1234-1241. doi: 10.1172/JCI114558.
57. Wang R, Lagakos SW, Ware JH, Hunter DJ, Drazen JM. Statistics in medicine-reporting of subgroup analyses in clinical trials. N Engl J Med. 2007;357:2189-2194. doi: 10.1056/NEJMsr077003.
58. Cockerill GW, Rye KA, Gamble JR, Vadas MA, Barter PJ. High-density lipoproteins inhibit cytokine-induced expression of endothelial cell adhesion molecules. Arterioscler Thromb Vasc Biol. 1995;15:1987-1994.
59. Nicholls SJ, Dusting GJ, Cutri B, Bao S, Drummond GR, Rye KA, Barter PJ. Reconstituted high-density lipoproteins inhibit the acute pro-oxidant and proinflammatory vascular changes induced by a periarterial collar in normocholesterolemic rabbits. Circulation. 2005;111:1543-1550. doi: 10.1161/01.CIR.0000159351.95399.50.
60. Wu BJ, Chen K, Shrestha S, Ong KL, Barter PJ, Rye KA. Highdensity lipoproteins inhibit vascular endothelial inflammation by increasing 3β-hydroxysteroid-▵ 24 reductase expression and inducing heme oxygenase-1. Circ Res. 2013;112:278-288. doi: 10.1161/ CIRCRESAHA.111.300104.
61. Schulick AH, Vassalli G, Dunn PF, Dong G, Rade JJ, Zamarron C, Dichek DA. Established immunity precludes adenovirus-mediated gene transfer in rat carotid arteries. Potential for immunosuppression and vector engineering to overcome barriers of immunity. J Clin Invest. 1997;99:209-219. doi: 10.1172/JCI119149.
62. Van-Assche T, Huygelen V, Crabtree MJ, Antoniades C. Gene delivery strategies targeting stable atheromatous plaque. Curr Pharm Des. 2013;19:1626-1637.
63. Muck-Hausl M, Solanki M, Zhang W, Ruzsics Z, Ehrhardt A. Ad 2.0: a novel recombineering platform for high-throughput generation of tailored adenoviruses. Nucleic Acids Res. 2015;43:e50. doi: 10.1093/nar/gkv031.